Celltrion Pharm said on the 24th it presented research results on next-generation cancer drugs at the American Association for Cancer Research. Celltrion Pharm unveiled an antibody-drug conjugate (ADC) that combines two types of drugs (payloads).
An ADC is a technology that attaches a drug to an antibody to precisely treat only cancer cells, and is called a "guided missile that targets cancer cells." Antibodies recognize and bind to antigens on the surface of cancer cells. Celltrion Pharm is developing a dual-payload ADC that combines different drugs to maximize treatment effects.
Celltrion Pharm disclosed research results for its drug candidates CTPH-03 and CTPH-08. By combining a new drug with existing anticancer drugs, it enhanced efficacy and suggested the potential to overcome the problem of developing resistance to the drug.
A Celltrion Pharm official said, "We will secure competitiveness in the next-generation ADC market."